Switching to Iloperidone From Other Antipsychotics in Schizophrenia

• Status: Completed
• Trial end date: 2012-01-01
• Target enrollment: 0
• Participant gender: All

Summary

Evaluate the clinical outcome of two switching strategies to iloperidone treatment in adult subjects with schizophrenia who require a change in their current antipsychotic treatment of risperidone, olanzapine, or aripiprazole due to suboptimal efficacy and/or safety/tolerability reasons.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novartis
• Treatments: Aripiprazole; Iloperidone; Olanzapine; Risperidone

Criteria

Inclusion Criteria:

• Males or females, 18 to 64 years of age, inclusive

• DSM-IV diagnosis of schizophrenia

• Patients currently on an optimal in-label dose of one of the following permitted antipsychotic treatments for at least 30 days: risperidone, olanzapine, or aripiprazole

• Efficacy Clinical Global Impression of Severity (E-CGI-S) of 4 or 5 or

• Not tolerating one of the permitted treatments and exhibits one of the allowable side-effects

Exclusion Criteria:

• Any other current Axis I disorder other than schizophrenia which is the focus of treatment;

• Acutely psychotic or patient's symptom severity requires hospitalization

• Patient with significant cardiovascular illness (myocardial infarction, cardiac arrhythmia)

Other protocol-defined inclusion/exclusion criteria may apply